SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.
Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.
HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)
Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.
Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.
HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)
